| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 514.27 | 75.7% | 65.4% |
| Total Income | 516.07 | 71.7% | 63.7% |
| Expenditure | 386.64 | 36.6% | 45.5% |
| PBT | 129.44 | 636.7% | 161.9% |
| Net Profit | 96.85 | 596.8% | 194.9% |
| OPM | 30.25% | 18.47pp | 21.26pp |
| NPM | 18.77% | 14.15pp | 8.35pp |
| EPS | 75.49 | 597.0% | 194.9% |
Neuland Laboratories Reports Q2FY26 Total Income at Rs.516.1 Crore, EBITDA at Rs.156.9 Crore
07 Nov 2025 · 7 Nov 2025, 04:31 pm
Summary
Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, announced financial results for the half year ended Sep 30, 2025. The company reported a total income of Rs.516.1 crore and EBITDA of Rs.156.9 crore for Q2FY26.
Key Highlights
- 1
Q2FY26 Total income at Rs.516.1 crore
- 2
EBITDA at Rs.156.9 crore
- 3
YoY increase of 63.70% in total income
- 4
YoY increase of 138.80% in EBITDA
- 5
QoQ increase of 71.70% in total income
- 6
QoQ increase of 272.70% in EBITDA
- 7
Profit Before Tax (PBT) at Rs.129.0 crore
- 8
PBT Margin at 25.00%
- 9
Profit After Tax (PAT) at Rs.96.5 crore
- 10
PAT Margin at 19.21%
Management Comments
Mr. Sucheth Davuluri
Vice-Chairman and Chief Executive Officer
The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.
Mr. Saharsh Davuluri
Vice Chairman and Managing Director
Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.
Informational and educational content only. Not investment advice.